Pedro Romero

TiGenix (Spain) — Spain

Immunology and Microbiology · Life Sciences

101h-index37.2kcitations676works13.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(352), Immune Cell Function and Interaction(215), Cancer Immunotherapy and Biomarkers(183), T-cell and B-cell Immunology(180), CAR-T cell therapy research(160)

Publications675 total

NK receptor signaling lowers the TCR activation threshold: role in selective recognition of cancer cells, but not healthy tissues, by TAA-specific CTLs 2687
The Journal of Immunology·2025Open Access
Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer
Science Advances·2025· 3 citedOpen Access
What is the folk concept of remembering?
2025Open Access
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer
JCI Insight·2025· 3 citedOpen Access
PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Immunotherapy and Tumor Resistance to Immune-Mediated Control and Elimination
Elsevier eBooks·2025
P337: Variant classification is negatively impacted by the absence of biochemical data in published patient reports
Genetics in Medicine Open·2025Open Access
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression
Journal for ImmunoTherapy of Cancer·2024· 5 citedOpen Access
A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy
Molecular Therapy Oncology·2024· 4 citedOpen Access
Resectable Non-Small Cell Lung Cancer Heterogeneity and Recurrence Assessed by Tissue Next-Generation Sequencing Genotyping and Circulating Tumor Cell EZH2 Characterization
Archivos de Bronconeumología·2024· 1 cited
Figure S4 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Figure S2 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Figure S1 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Figure S7 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Data from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Figure S5 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Figure S6 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Figure S3 from NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs
2024Open Access
Jeffrey S Weber, MD, PhD (1952–2024): in memoriam to discovery, friendship and family
Journal for ImmunoTherapy of Cancer·2024· 1 citedOpen Access
page 1 of 34Next →

Frequent Co-authors

Daniel E. Speiser(14), Donata Rimoldi(8), Jean‐Charles Cerottini(7), Camilla Jandus(7), Danila Valmori(6), Nathalie Rufer(6), Danielle Líénard(6), Mikäel J. Pittet(6), Ping‐Chih Ho(5), George Coukos(5), Ferdy J. Lejeune(4), Mathias Wenes(3), Olivier Michielin(3), P. Rod Dunbar(3), Vincenzo Cerundolo(3), Gilles Bioley(3), Pascal Schneider(2), Jürg Tschopp(2), Éric Vivier(2), Jean‐Laurent Casanova(2)